Impact of Abcg2, Oct1 And Abcb1 (Mdr1) Gene Expression on Treatment-Free Remission In A Euro-Ski Subtrial

Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response (DMR). ABCG2, OCT1 and ABCB1 (MDR1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated.

Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: S ébastien Rinaldetti, Markus Pfirmann, Kirsi Manz, Joelle Guilhot, Christian Dietz, Panayiotidis Panagiotidis, Birgit Spiess, Wolfgang Seifarth, Alice Fabarius, Martin Müller, Maria Pagoni, Maria Dimou, Jolanta Dengler, Cornelius Waller, Tim H. Brümme Tags: Original Study Source Type: research